Investment Analysts’ Recent Ratings Changes for Tenet Healthcare (THC)

Several brokerages have updated their recommendations and price targets on shares of Tenet Healthcare (NYSE: THC) in the last few weeks:

• 5/14/2025 – Tenet Healthcare had its price target raised by analysts at Bank of America Co. from $165.00 to $180.00. They now have a “buy” rating on the stock.
• 5/12/2025 – Tenet Healthcare had its price target raised by analysts at Truist Financial Co. from $175.00 to $190.00. They now have a “buy” rating on the stock.
• 5/5/2025 – Tenet Healthcare had its price target raised by analysts at Morgan Stanley from $165.00 to $175.00. They now have an “overweight” rating on the stock.
• 5/5/2025 – Tenet Healthcare had its price target raised by analysts at The Goldman Sachs Group, Inc. from $134.00 to $154.00. They now have a “neutral” rating on the stock.
• 5/1/2025 – Tenet Healthcare was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating.
• 4/30/2025 – Tenet Healthcare had its price target raised by analysts at Barclays PLC from $161.00 to $171.00. They now have an “overweight” rating on the stock.
• 4/30/2025 – Tenet Healthcare had its price target raised by analysts at Royal Bank of Canada from $183.00 to $189.00. They now have an “outperform” rating on the stock.
• 4/30/2025 – Tenet Healthcare had its price target raised by analysts at UBS Group AG from $217.00 to $230.00. They now have a “buy” rating on the stock.
• 4/15/2025 – Tenet Healthcare had its “neutral” rating reaffirmed by analysts at Robert W. Baird. They now have a $137.00 price target on the stock, down previously from $153.00.
• 4/15/2025 – Tenet Healthcare was downgraded by analysts at Baird R W from a “strong-buy” rating to a “hold” rating.
• 4/9/2025 – Tenet Healthcare is now covered by analysts at Guggenheim. They set a “buy” rating and a $165.00 price target on the stock.
• 3/26/2025 – Tenet Healthcare is now covered by analysts at Morgan Stanley. They set an “overweight” rating and a $165.00 price target on the stock.

Tenet Healthcare Price Performance

THC traded up $1.82 during trading on Tuesday, hitting $169.10. 394,001 shares of the company traded hands, compared to its average volume of 1,540,889. The company has a market cap of $15.71 billion, a PE ratio of 5.25, a P/E/G ratio of 1.02 and a beta of 1.63. The stock’s 50-day simple moving average is $133.70 and its two-hundred day simple moving average is $136.23. The company has a current ratio of 1.78, a quick ratio of 1.70 and a debt-to-equity ratio of 2.25. Tenet Healthcare Co. has a 1 year low of $109.82 and a 1 year high of $171.20.

Tenet Healthcare (NYSE:THC) last announced its quarterly earnings results on Tuesday, April 29th. The company reported $4.36 EPS for the quarter, beating analysts’ consensus estimates of $3.11 by $1.25. Tenet Healthcare had a net margin of 15.48% and a return on equity of 21.88%. The firm had revenue of $5.22 billion during the quarter, compared to the consensus estimate of $5.15 billion. During the same quarter last year, the firm earned $3.22 EPS. The firm’s revenue for the quarter was down 2.5% compared to the same quarter last year. As a group, sell-side analysts anticipate that Tenet Healthcare Co. will post 12.24 earnings per share for the current fiscal year.

Insider Activity

In related news, Director J Robert Kerrey sold 9,525 shares of the stock in a transaction that occurred on Tuesday, March 11th. The shares were sold at an average price of $125.43, for a total value of $1,194,720.75. Following the completion of the transaction, the director now directly owns 27,378 shares of the company’s stock, valued at $3,434,022.54. This trade represents a 25.81% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Paola M. Arbour sold 6,461 shares of the business’s stock in a transaction on Thursday, May 15th. The shares were sold at an average price of $160.20, for a total transaction of $1,035,052.20. Following the sale, the executive vice president now directly owns 27,848 shares in the company, valued at $4,461,249.60. This trade represents a 18.83% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 20,987 shares of company stock worth $2,972,421. 0.81% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Tenet Healthcare

Several hedge funds and other institutional investors have recently added to or reduced their stakes in THC. Crossmark Global Holdings Inc. grew its position in Tenet Healthcare by 41.1% during the fourth quarter. Crossmark Global Holdings Inc. now owns 8,731 shares of the company’s stock valued at $1,102,000 after buying an additional 2,544 shares during the period. SG Americas Securities LLC raised its stake in Tenet Healthcare by 81.9% in the 4th quarter. SG Americas Securities LLC now owns 8,077 shares of the company’s stock valued at $1,020,000 after purchasing an additional 3,637 shares during the last quarter. Inspire Investing LLC grew its stake in Tenet Healthcare by 25.6% during the 4th quarter. Inspire Investing LLC now owns 6,496 shares of the company’s stock valued at $820,000 after acquiring an additional 1,326 shares in the last quarter. Impact Partnership Wealth LLC purchased a new stake in shares of Tenet Healthcare in the fourth quarter valued at approximately $338,000. Finally, Flagship Harbor Advisors LLC raised its holdings in shares of Tenet Healthcare by 20.8% during the 4th quarter. Flagship Harbor Advisors LLC now owns 1,655 shares of the company’s stock worth $209,000 after acquiring an additional 285 shares during the period. 95.44% of the stock is owned by institutional investors and hedge funds.

Tenet Healthcare Corporation operates as a diversified healthcare services company in the United States. The company operates through two segments: Hospital Operations and Services, and Ambulatory Care. Its general hospitals offer acute care services, operating and recovery rooms, radiology and respiratory therapy services, clinical laboratories, and pharmacies.